BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 07, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AVI-4658: Additional Phase Ib/II data

Top-line biopsy data from the ongoing, open-label, dose-escalation, U.K. Phase Ib/II Study 28 trial in 19 patients showed that all 8 patients receiving 10 or 20 mg/kg weekly AVI-4658 generated new dystrophin-positive muscle fibers with consistent skipping of exon 51 in dystrophin mRNA at week 12....

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >